A.R.T. Advisors’s Abeona Therapeutics ABEO Stock Holding History

A.R.T. Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-404	Closed	-$33K	–	34
2019 Q4	$33K	Buy	+404	New	+$28.5K	﹤0.01%	1266
2019 Q3	–	Sell	-684	Closed	-$82K	–	1392
2019 Q2	$82K	Buy	+684	New	+$115K	﹤0.01%	1219
2018 Q4	–	Sell	-555	Closed	-$177K	–	1269
2018 Q3	$177K	Buy	+555	New	+$197K	0.01%	1212
2018 Q1	–	Sell	-1,185	Closed	-$469K	–	1462
2017 Q4	$469K	Buy	+1,185	New	+$490K	0.02%	923
2017 Q1	–	Sell	-968	Closed	-$117K	–	1388
2016 Q4	$117K	Buy	+968	New	+$152K	0.01%	1128

Other funds holding ABEO

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

A.R.T. Advisors's ABEO Position: Q1 2020 in Review

A.R.T. Advisors sold out of Abeona Therapeutics (ABEO) in Q1 2020, closing a stake of 404 shares — an estimated $33K sold.

A.R.T. Advisors first reported a position in ABEO in Q4 2016 and held it in 5 quarters. The position peaked at $469K in Q4 2017. 80 funds tracked by Wall St. Rank hold ABEO as of Q1 2020.

A.R.T. Advisors reported no remaining Abeona Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 404 Abeona Therapeutics shares in Q1 2020, an estimated $33K.
A.R.T. Advisors first reported a position in Abeona Therapeutics in Q4 2016 and held it in 5 quarters.
A.R.T. Advisors's Abeona Therapeutics position peaked at $469K in Q4 2017.
80 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.